Literature DB >> 1697685

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.

D J Good1, P J Polverini, F Rastinejad, M M Le Beau, R S Lemons, W A Frazier, N P Bouck.   

Abstract

A secreted inhibitor of angiogenesis that is controlled by a tumor suppressor gene in hamster cells has been found to be similar to a fragment of the platelet and matrix protein thrombospondin. The two proteins were biochemically similar and immunologically crossreactive and could substitute for one another in two functional assays. Human thrombospondin inhibited neovascularization in vivo and endothelial cell migration in vitro, as does the hamster protein, gp140. gp140 sensitized smooth muscle cells to stimulation by epidermal growth factor, as does human thrombospondin. The thrombospondin gene has been localized on human chromosome 15. These results demonstrate a function for the ubiquitous adhesive glycoprotein thrombospondin that is likely to be important in the normal physiological down-regulation of neovascularization. In addition, they raise the possibility that thrombospondin may be one of a number of target molecules through which a tumor suppressor gene could act to restrain tumor growth.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697685      PMCID: PMC54589          DOI: 10.1073/pnas.87.17.6624

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Isolation and properties of a thrombin-sensitive protein of human platelets.

Authors:  N L Baenziger; G N Brodie; P W Majerus
Journal:  J Biol Chem       Date:  1972-05-10       Impact factor: 5.157

Review 2.  The structural and functional properties of thrombospondin.

Authors:  J Lawler
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

Review 3.  Interactions of thrombospondin with cells in culture: rapid degradation of both soluble and matrix thrombospondin.

Authors:  J E Murphy-Ullrich; D F Mosher
Journal:  Semin Thromb Hemost       Date:  1987-07       Impact factor: 4.180

4.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

5.  Effects of anti-thrombospondin monoclonal antibodies on the agglutination of erythrocytes and fixed, activated platelets by purified thrombospondin.

Authors:  V M Dixit; D M Haverstick; K M O'Rourke; S W Hennessy; G A Grant; S A Santoro; W A Frazier
Journal:  Biochemistry       Date:  1985-07-30       Impact factor: 3.162

6.  Monoclonal antibodies that recognize calcium-dependent structures of human thrombospondin. Characterization and mapping of their epitopes.

Authors:  V M Dixit; N J Galvin; K M O'Rourke; W A Frazier
Journal:  J Biol Chem       Date:  1986-02-05       Impact factor: 5.157

7.  Identification of a single chromosome in the normal human genome essential for suppression of hamster cell transformation.

Authors:  A Stoler; N Bouck
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

8.  Synthesis, intracellular processing and secretion of thrombospondin in human endothelial cells.

Authors:  P Vischer; H Beeck; B Voss
Journal:  Eur J Biochem       Date:  1985-12-16

9.  Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon.

Authors:  L Zardi; B Carnemolla; A Siri; T E Petersen; G Paolella; G Sebastio; F E Baralle
Journal:  EMBO J       Date:  1987-08       Impact factor: 11.598

10.  Mapping of epitopes for monoclonal antibodies against human platelet thrombospondin with electron microscopy and high sensitivity amino acid sequencing.

Authors:  N J Galvin; V M Dixit; K M O'Rourke; S A Santoro; G A Grant; W A Frazier
Journal:  J Cell Biol       Date:  1985-10       Impact factor: 10.539

View more
  282 in total

Review 1.  Anticancer drug targets: approaching angiogenesis.

Authors:  E Keshet; S A Ben-Sasson
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  Thrombospondins as matricellular modulators of cell function.

Authors:  P Bornstein
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 3.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

4.  A novel in vitro model of tumor angiogenesis.

Authors:  D Kozien; M Gerol; B Hendey; A RayChaudhury
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-10       Impact factor: 2.416

Review 5.  Science, medicine, and the future. Antivascular therapy: a new approach to cancer treatment.

Authors:  A J Hayes; L Y Li; M E Lippman
Journal:  BMJ       Date:  1999-03-27

Review 6.  The role of angiogenesis in rheumatoid arthritis: recent developments.

Authors:  A E Koch
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 7.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism.

Authors:  M Febbraio; D P Hajjar; R L Silverstein
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

8.  Cell contact-dependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1.

Authors:  L Chandrasekaran; C Z He; H Al-Barazi; H C Krutzsch; M L Iruela-Arispe; D D Roberts
Journal:  Mol Biol Cell       Date:  2000-09       Impact factor: 4.138

Review 9.  Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored.

Authors:  Jan Buter; Herbert M Pinedo
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

10.  Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.

Authors:  Philip P Fitchev; Susan M Wcislak; Chung Lee; Anders Bergh; Charles B Brendler; Veronica M Stellmach; Susan E Crawford; Constantine D Mavroudis; Mona L Cornwell; Jennifer A Doll
Journal:  Lab Invest       Date:  2010-05-10       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.